Related Experiment Video
Updated: Dec 23, 2025
05:17
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
1.9K
New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2.
Rania Hamdy1,2,3, Samia A Elseginy4,5,6, Noha I Ziedan7,8,9
1School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, Wales CF10 3NB, UK. rania_hamdy2000@yahoo.com.
Molecules (Basel, Switzerland)
|April 17, 2019
Summary
Researchers developed novel quinoline-based compounds targeting the Bcl-2 protein, a key factor in cancer cell survival. Some analogues showed significant anticancer activity, offering potential for new cancer therapies.
Area of Science:
- Medicinal Chemistry
- Drug Discovery
- Molecular Biology
Background:
- Bcl-2 protein is a crucial target for anticancer drug development due to its role in preventing apoptosis.
- Venetoclax, a BH3 domain mimetic, is approved for chronic lymphocytic leukemia, validating Bcl-2 as a target.
- Previous research focused on indole-based Bcl-2 inhibitors.
Purpose of the Study:
- To identify novel quinolin-4-yl based oxadiazole and triazole analogues as Bcl-2 inhibitors.
- To synthesize and evaluate the anticancer potential of these new heterocyclic compounds.
- To explore structure-activity relationships and computational insights for further drug design.
Main Methods:
- Synthesis of target compounds via a common aryl-substituted quinolin-4-carbonyl-N-arylhydrazine-1-carbothioamide intermediate.
- Evaluation of anti-proliferative activity in Bcl-2-expressing cancer cell lines.
- Bcl2-Bim peptide ELISA assay to determine inhibitory concentration (IC50).
- Computational molecular modeling to rationalize Bcl-2 targeted activity.
Main Results:
- Novel quinoline-based oxadiazole and triazole analogues were successfully synthesized.
- Compound 6i and other analogues demonstrated sub-micromolar anti-proliferative activity against cancer cell lines.
- Sub-micromolar IC50 values were observed in the Bcl2-Bim peptide ELISA assay.
- Molecular modeling provided insights into the mechanism of Bcl-2 inhibition by compound 6i.
Conclusions:
- Quinoline-based oxadiazole analogues show promising anticancer activity by inhibiting Bcl-2.
- Compound 6i is a potent Bcl-2 inhibitor with therapeutic potential.
- This study provides a foundation for designing more selective and potent Bcl-2 inhibitory heteroaromatics.
